H.B. Fuller Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Mar 26, 2025, 12:41 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Earnings expectations are significantly lower than previous year, reflecting poor performance. Historical examples show earnings misses often lead to stock price declines.
AI summary
What happened, with direct paths to the underlying reporting
H.B. Fuller will release Q1 results on March 26. Analysts predict earnings of 50 cents per share, down from 67 cents last year. Revenue for the quarter is projected at $769.11 million, a decline from $810.42 million. The stock recently closed down 1.1% at $53.83. Analysts' ratings on FUL show mixed sentiments, with downgrades impacting outlook.
H.B. Fuller will release Q1 results on March 26.
Analysts predict earnings of 50 cents per share, down from 67 cents last year.
Revenue for the quarter is projected at $769.11 million, a decline from $810.42 million.
The stock recently closed down 1.1% at $53.83.
Analysts' ratings on FUL show mixed sentiments, with downgrades impacting outlook.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
HB Fuller has offered to acquire AMS for £715 million in cash, expanding its medical adhesives platform and driving higher-margin growth. The deal widens HB Fuller’s total address…
H.B. Fuller reports Q2 results after the close on June 24. Analysts expect EPS of $1.38 on about $923.6 million in revenue, and the company recently raised the dividend by 4.3%. A…
H.B. Fuller has made an unsolicited offer to acquire Advanced Medical Solutions, which may enhance Fuller’s healthcare product offerings following a failed previous buyout. This s…
J.P. Morgan maintains Underweight rating on FUL, lowering forecast to $50. First-quarter revenue fell 2.7% to $789 million, organic growth up 1.9%. Health segment saw EBITDA drop…